Results 21 to 30 of about 178,848,266 (217)
Medication-related osteonecrosis of the jaw (MRONJ) frequently affects patients after treatments with bisphosphonates or denosumab, especially with high doses in patients with bone osteoporosis, neoplastic metastases, or possibly anti-angiogenic ...
Antonio Cortese +3 more
doaj +1 more source
Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw [PDF]
The anti-angiogenic effects of bisphosphonates have been hypothesized as one of the major etiologic factors in the development of medication-related osteonecrosis of the jaw (MRONJ), a severe debilitating condition with limited treatment options.
Petcu, Eugen Bogdan +5 more
core +1 more source
The Prevention of Medication-related Osteonecrosis of the Jaw [PDF]
Medication-related osteonecrosis of the jaw (MRONJ) is a preventable complication of antiresorptive treatment. It arises in 1-20% of patients with bone metastases of solid tumors and hematologic malignancies and in 0.1-2% of patients being treated for osteoporosis with bisphosphonates. Depending on the underlying disease and medication dosage, the risk
Poxleitner, Philipp +3 more
openaire +3 more sources
Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj +1 more source
Fatal infectious encephalitis as a complication of medication-related osteonecrosis of the jaw
We present a unique case of bacterial encephalitis in a 79-year-old female due to progression of medication-related osteonecrosis of the jaw. The occurrence of this life-threatening neurologic condition following the expansion of medication-related ...
Hye-Won Kim +3 more
doaj +1 more source
The Use of Photodynamic Therapy on Medication-Related Osteonecrosis of the Jaws: Animal Study
Background/Aim: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first introduced in 2003 and its scope was expanded by the name medication-related osteonecrosis of the jaw (MRONJ), since 2014.
Karapinar Gökay +3 more
doaj +1 more source
Osteonecrosis of The Jaw; Medication- Related Osteonecrosis of the jaw (MRONJ)
Sejak tahun 2004, dilaporkan terjadinya osteonecrosis of the jaw pada pasien osteoporosis yang mengkonsumsi bifosfonat, walaupun hal tersebut lebih sedikir dibandingkan kejadian osteonecrosis of the jaw pada penderita kanker yang mendapat terapi bifosfonat secara intravena.
openaire +2 more sources
Summary: Generally, CT and MR images of antiresorptive agent-related osteonecrosis of the jaw (ARONJ)/medication-related osteonecrosis of the jaw (MRONJ) show nonspecific findings as seen in active osteomyelitis.However, there are some characteristics as
Akira Baba +6 more
doaj +1 more source
Medication-related osteonecrosis of the jaw: An update
Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma. Unfortunately, they are also associated with a rare but devastating side effect - medication-related osteonecrosis of the jaw (MRONJ). First reported in 2003, much research
openaire +2 more sources
Plasma Therapy for Medication-Related Osteonecrosis of the Jaws- A Case Report
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of anti-bone resorption medications. Nowadays antiresorptive medications like bisphosphonate and monoclonal antibodies like denosumab that have been prescribed for bone disorders and ...
Maryam Jalili Sadrabad, Elham Saberian
doaj +1 more source

